Vietnam’s pharmaceutical market is expected to have a year of optimism after experiencing a multicoloured gamut in 2024.

"Trump might forget about Greenland. But also, he might not. Nobody knows. He operates on whims," @anneapplebaum writes.

Can philanthropy fill the gap left by the closure of USAID? Unlikely, say the experts — but it can do something.

These diabetes and weight loss drugs work by slowing digestion and curbing ... In a statement sent to USA TODAY, a spokesperson for drug maker Novo Nordisk said the company welcomes any ...

where Novo Nordisk, the maker of Ozempic and Wegovy is based.) These drugs have also been given partial credit for a recent dip in obesity rates in the US, which dropped in 2023 for the first time in ...

and to work with like-minded suppliers. One way to ensure that Novo Nordisk’s approach to sustainability is carried through all parts of the business has been the way it has approached educating ...

More: Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations These diabetes and weight loss drugs work by slowing digestion and ... a spokesperson for drug maker Novo ...

All authors approved the final version of the manuscript, including the authorship list, and agreed to be accountable for all aspects of the work in ensuring that questions ... Inc., NGM ...

Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...